Seraphina Therapeutics

Today's coverage from Longevity Technology https://lnkd.in/gChPjubu

An exciting new clinical trial was just published in The Journal of Nutrition supporting that @fatty15 can treat nutritional C15:0 deficiencies and reverse Cellular Fragility Syndrome. Cellular Fragility Syndrome, caused by low C15:0 levels, is the first nutritional deficiency syndrome to be identified in over 75 years. Studies support that Cellular Fragility Syndrome may be present in as many as 1 in 3 people, leading to accelerated aging and onset of aging-related conditions. The good news is that C15:0 nutritional deficiencies can be easily identified and treated. This randomized, double-blinded, and placebo-controlled trial included young adults (18 to 24 years old) and was led by UC San Diego. Here are key findings from this important study: 1) 2 out of 3 study participants had C15:0 levels that met the criteria of nutritional C15:0 deficiency, 2) fatty15 safely and significantly raised C15:0 blood levels, and 3) those who achieved nutritionally sufficient C15:0 blood levels had clinically relevant evidence of reversing Cellular Fragility Syndrome, including improved liver function and red blood cell health. Go, science. Check out NutraIngredients coverage of this latest clinical trial!

Twelve years ago, a new form of cell death was discovered by a team of researchers at Columbia University. It’s called ferroptosis. Over 10,000 scientific papers have been published on ferroptosis, and we now know that it can accelerate aging, type 2 diabetes, heart disease, and fatty liver disease. The cause of ferroptosis has remained unknown. Until now. As published in Metabolites, a new nutritional C15:0 (pentadecanoic acid) deficiency syndrome has been discovered. Cellular Fragility Syndrome is the first nutritional deficiency syndrome to be discovered in 75 years and may be affecting as many as 1 in 3 of us. This paper is a culmination of 12 years of studies that explain C15:0’s role as an essential fatty acid, how low C15:0 levels results in cellular fragility, ferroptosis and impaired health, and most importantly, how replenishing our C15:0 levels fixes our cells, reverses ferroptosis, and restores metabolic, liver, and heart health. Population wide declines in C15:0 levels have been occurring due to 1) lower intake of whole dairy-fat foods (our primary source of C15:0, 2) lower C15:0 content in dairy due to changing agricultural practices, and 3) aging - our C15:0 levels naturally decline as we get older. The good news is that nutritional deficiency syndromes are detectable and fixable. It’s time to revisit nutritional guidelines and agriculture industry practices to get C15:0 back into our lives. Read the study: https://lnkd.in/gDtfHMHr

Dear LinkedIn community, I'm thrilled to share groundbreaking news from the world of science and health that has the potential to revolutionize our approach to aging and longevity. Today the scientific journal Nutrients published our discovery, demonstrating that C15:0 (pentadecanoic acid), an odd-chain saturated fat, is emerging as an essential nutrient with profound benefits expected to enhance human longevity. The study reveals that C15:0 exhibits anti-aging mechanisms that not only equal, but surpass, leading prescription drug longevity candidates. This essential fatty acid, the first to be discovered in over 90 years since omega-3, has long been associated with lower risks of type 2 diabetes, heart disease, nonalcoholic fatty liver disease, and cancer. However, recent research has shed light on the specific anti-aging processes driven by C15:0, making it a powerful contender in the quest for longevity. In this study, pure C15:0 (FA15™) was independently tested against three leading longevity drug candidates: rapamycin, metformin, and acarbose. The results showed that pure C15:0 was the most effective at repairing cells across various chronic disease states. C15:0 and rapamycin shared an impressive 24 clinically relevant activities across 10 out of the 12 human cell systems evaluated, including anti-inflammatory, anticancer, antifibrotic, and antimicrobial activities. Importantly, both C15:0 and rapamycin have been shown to inhibit mTOR, a key factor in extending human longevity. Dr. Nicholas Schork, co-author of the study and Principal Investigator for the National Institutes of Health’s Longevity Consortium, emphasizes the significance of these findings. He notes that the multitude of benefits offered by C15:0, which match or exceed those of leading longevity drugs, underscores the essential role of C15:0 in our long-term health. Of particular urgency, mounting science supports that nutritional C15:0 deficiencies may be contributing to the rising incidence of chronic diseases, especially among younger individuals, including nonalcoholic fatty liver disease (NAFLD). In a world where global health is declining, this discovery offers us a new and tangible hope. The ability to replenish our C15:0 levels through dietary sources or supplements has the potential to restore aspects of our long-term health and extend longevity for all. I invite you to learn more about this groundbreaking research and its implications for human health on our website, DiscoverC15.com, and fatty15.com. As co-founder and CEO of Seraphina Therapeutics, I am deeply excited about the potential of C15:0 to transform the way we think about aging and longevity. Together, we may be on the brink of a profound shift in the pursuit of a longer, healthier life. Nerd out on our latest study: https://lnkd.in/gWfAsUax #AntiAging #Longevity #HealthResearch #SeraphinaTherapeutics #DiscoverC15 #ScientificBreakthrough